AR059432A1 - Anticuerpos anti-fgf19 y metodos que usan estos - Google Patents

Anticuerpos anti-fgf19 y metodos que usan estos

Info

Publication number
AR059432A1
AR059432A1 ARP070100563A ARP070100563A AR059432A1 AR 059432 A1 AR059432 A1 AR 059432A1 AR P070100563 A ARP070100563 A AR P070100563A AR P070100563 A ARP070100563 A AR P070100563A AR 059432 A1 AR059432 A1 AR 059432A1
Authority
AR
Argentina
Prior art keywords
sequence
hvr
methods
fgf19
antibodies
Prior art date
Application number
ARP070100563A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR059432A1 publication Critical patent/AR059432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

La presente solicitud proporciona anticuerpos anti-FGF19 y composiciones que comprenden estos anticuerpos y métodos de usar los mismos, métodos que utilizan anticuerpos anti-FGF19 y métodos que comprenden la deteccion de FGF19 y/o FGFR4. Reivindicacion 1: Un anticuerpo anti-FGF19 que comprende: al menos uno, dos, tres, cuatro, cinco y/o seis secuencias de la region hipervariable (HVR) seleccionadas entre el grupo formado por: (a) HVR-L1 que comprende la secuencia KASQDINSFLS (identificador de secuencia n°:1); (b) HVR-L2 que comprende la secuencia YRANRLVD (identificador de secuencia n°:2); (c) HVR-L3 que comprende la secuencia LQYDEFPLT (identificador de secuencia n°:3); (d) HVR-H1 que comprende la secuencia TYGVH (identificador de secuencia n°:5); (e) HVR-H2 que comprende la secuencia VIWPGGGTDYNAAFIS (identificador de secuencia n°:6); y (f) HVR-H3 que comprende la secuencia KEYANLYAMDY (identificador de secuencia n°:7).
ARP070100563A 2006-02-10 2007-02-09 Anticuerpos anti-fgf19 y metodos que usan estos AR059432A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US78060806P 2006-03-09 2006-03-09
US88586607P 2007-01-19 2007-01-19

Publications (1)

Publication Number Publication Date
AR059432A1 true AR059432A1 (es) 2008-04-09

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100563A AR059432A1 (es) 2006-02-10 2007-02-09 Anticuerpos anti-fgf19 y metodos que usan estos

Country Status (11)

Country Link
US (4) US7678373B2 (es)
EP (1) EP1989230B1 (es)
JP (1) JP5209505B2 (es)
AR (1) AR059432A1 (es)
AU (1) AU2007254005B2 (es)
CA (1) CA2637988A1 (es)
ES (1) ES2582652T3 (es)
HK (1) HK1120273A1 (es)
NZ (1) NZ569957A (es)
TW (1) TWI388568B (es)
WO (1) WO2007136893A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
EP2039766A4 (en) * 2006-06-05 2010-06-16 Univ Hiroshima IMMUNOCOMPETENT CELL HAVING ANTI-CD38 ANTIBODY ON ITS SURFACE
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
EP2550972B1 (en) * 2007-04-02 2018-02-21 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
EP2280994A4 (en) * 2008-04-30 2011-05-25 Wntres Ab RESTORATION OF ESTROGEN RECEPTOR ACTIVITY
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8535912B2 (en) * 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2683736B1 (en) 2011-03-09 2018-01-17 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
AU2012318247B2 (en) 2011-11-14 2015-12-17 Five Prime Therapeutics, Inc. Methods of treating cancer
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
CN104168920A (zh) * 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 使用fgf19调控剂的方法
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
ES2865303T3 (es) * 2013-12-20 2021-10-15 Angiobiomed Gmbh Ligante de adrenomedulina para su uso en la terapia del cáncer
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
KR102569907B1 (ko) * 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
JP6695353B2 (ja) 2015-03-25 2020-05-20 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
CN109071659B (zh) 2016-02-10 2022-06-10 生物发明国际股份公司 人抗fgfr4抗体和索拉非尼的组合
WO2017200016A1 (ja) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
PT3534902T (pt) 2016-11-02 2022-12-07 Novartis Ag Combinações de inibidores de fgfr4 e quelantes de ácidos biliares
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
EP3917956A4 (en) * 2019-02-02 2022-12-07 Huahui Health Ltd. ANTI-FGF19 ANTIBODIES
PT3865155T (pt) * 2020-02-13 2023-01-02 Orano Med Processo para modificação específica de local de um anticorpo
TW202402797A (zh) 2022-05-19 2024-01-16 美商泰拉生物科學公司 使用ppar促效劑及fgfr4抑制劑之療法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
WO1999027100A1 (en) 1997-11-25 1999-06-03 Genentech, Inc. Fibroblast growth factor-19
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
WO2001018210A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1268793A2 (en) 2000-03-22 2003-01-02 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003065006A2 (en) 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2005528905A (ja) * 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
AU2007254005B2 (en) * 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same

Also Published As

Publication number Publication date
NZ569957A (en) 2012-03-30
ES2582652T3 (es) 2016-09-14
US20100129381A1 (en) 2010-05-27
JP2009525764A (ja) 2009-07-16
US7678373B2 (en) 2010-03-16
EP1989230A2 (en) 2008-11-12
US7846691B2 (en) 2010-12-07
US20110086032A1 (en) 2011-04-14
HK1120273A1 (zh) 2009-03-27
US8293241B2 (en) 2012-10-23
EP1989230B1 (en) 2016-06-01
AU2007254005B2 (en) 2012-11-29
TWI388568B (zh) 2013-03-11
US20120128675A1 (en) 2012-05-24
WO2007136893A3 (en) 2008-05-15
WO2007136893A2 (en) 2007-11-29
JP5209505B2 (ja) 2013-06-12
CA2637988A1 (en) 2007-11-29
US8241633B2 (en) 2012-08-14
TW200808827A (en) 2008-02-16
US20070248604A1 (en) 2007-10-25
AU2007254005A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
AR059432A1 (es) Anticuerpos anti-fgf19 y metodos que usan estos
CO6220835A2 (es) Anticuerpos anti-robo4 y sus usos
RU2011134500A (ru) Антитела и иммуноконъюгаты и их применения
AR067544A1 (es) Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos
AR067543A1 (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CO6331344A2 (es) Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
HRP20171190T1 (hr) Protutijelo protiv beta-amiloida i njegove upotrebe
AR076030A1 (es) Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso
AR058932A1 (es) Anticuerpos anti-ephb4 y metodos que usan estos
CU24663B1 (es) Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo
AR082916A1 (es) Moleculas de union a 4-1bb
AR076029A1 (es) Anticuerpos anti- fcrh5 (receptor de translocacion asociado a la superfamilia de inmunoglobulina) e inmunoconjugados y metodos de uso
RS53258B (en) HUMAN ANTIBODIES AGAINST HEPATITIS C (HCV) VIRUS AND USE
RS53942B1 (en) Antibodies and Immunoconjugates and Their Use
RS53157B (en) SCLEROSTINE ANTIBODIES
JP2012116856A5 (es)
ES2628108T3 (es) Anticuerpos multiespecíficos
RS54452B1 (en) INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
AR076662A1 (es) Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120080A1 (es) Anticuerpos anti-notch2 y metodos de uso
NZ602040A (en) Anti-lrp6 antibodies
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização

Legal Events

Date Code Title Description
FC Refusal